Dade Behring goes public
This article was originally published in The Gray Sheet
Diagnostics firm completes pre-packaged Chapter 11 debt restructuring and enters the public market with a new board of directors Oct. 3. The firm expects to complete Nasdaq registration within six months; common equity initially will be traded over-the-counter, with prices listed in the pink sheets. In August, Dade Behring announced a debt-to-equity swap to cover $1.5 bil. in liabilities for the company, then privately held (1"The Gray Sheet" Aug. 5, 2002, p. 16)...
You may also be interested in...
Dade Behring's focus on growing its clinical lab diagnostics business while reducing debt, combined with a rising profile on Wall Street and plans to enter the high-volume testing category, are buoying the firm's stock price
Dade Behring anticipates launching a next-generation Dimension integrated chemistry analyzer system in "high-volume" laboratories in 2005, targeting a $5 bil. worldwide market
Diagnostics manufacturer Dade Behring hopes to emerge from its Aug. 1 Chapter 11 bankruptcy protection filing as a public company by October